Trial Profile
A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder; Dyslexia
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Mar 2008 New trial record.